Organovo Holdings, Inc. ONVO
Set alert
2.04 0.00 0.00%
At close · Apr 23
1.94 Day range 2.16
52-week range unavailable
- YTD
- -63.04%
- 1 year
- -83.00%
- Open
- 2.16
- Prev close
- 2.04
- Mkt cap
- 3.67M
- Vol
- 243.63K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.94
- High
- 2.16
- Forward P/E
- -0.45
- Beta
- 0.00
- Short ratio
- 0.47
- Inst. own
- 15.88%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 13, 2025
- 50-d avg
- 0.4226
- 200-d avg
- 0.6968
- 1y target
- 5.40
2Y chart
Events in this range
- Nov 9, 2023Earnings: -0.46; estimate -0.43; surprise -6.98%
- Feb 8, 2024Earnings: -0.4; estimate -0.41; surprise 2.44%
- May 31, 2024Earnings: -0.29; estimate -0.42; surprise 30.95%
- Aug 5, 2024Earnings: -0.23; estimate -0.38; surprise 39.47%
- Nov 8, 2024Earnings: -0.14; estimate -0.26; surprise 46.15%
- Feb 13, 2025Earnings: —; estimate -0.21; surprise —%
- Mar 21, 2025Split: 1 for 12
Signals (93)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 11, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 10, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 6, 2025 | 1 year ago |
| SMA: Bearish | Mar 5, 2025 | 1 year ago |
| SMA: Bullish | Feb 25, 2025 | 1 year ago |
| SMA: Bullish | Feb 25, 2025 | 1 year ago |
| RSI: Overbought | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| SMA: Bearish | Jan 10, 2025 | 1 year ago |
| SMA: Bullish | Dec 31, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 31, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 12, 2024 | 1 year ago |
| SMA: Bearish | Dec 10, 2024 | 1 year ago |
| SMA: Bullish | Nov 27, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 25, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 6, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 2, 2024 | 2 years ago |
Newest 20 of 93.
Key statistics
- Market cap
- 5.24M
- Enterprise value
- 3.53M
- Trailing P/E
- 0.00
- Forward P/E
- -0.45
- PEG ratio
- 0.00
- Price / sales
- 50.84
- Price / book
- 0.93
- EPS (TTM)
- -1.04
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 103.00K
- Revenue growth
- 0.00%
- Free cash flow
- -6.34M
- Total cash
- 3.17M
- Total debt
- 1.17M
- Return on equity
- -206.69%
- Shares outstanding
- 15.37M
- Short % of float
- 0.71%
- 50-day average
- 0.4226
- 200-day average
- 0.6968
Analyst view
Consensus: none
Price target (mean) 5.40
Next earnings
Feb 13, 2025
Expected Feb 13, 2025. Consensus EPS estimate 0.00.
Financials — quick view
ONVO Revenue — quarterly 24.00K
ONVO Net income — quarterly -3.45M
ONVO EPS — quarterly -2.28
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 13, 2025 | Dec 1, 2024 | -0.21 | — | — | — |
| Nov 8, 2024 | Sep 1, 2024 | -0.26 | -0.14 | +0.12 | +46.15% |
| Aug 5, 2024 | Jun 1, 2024 | -0.38 | -0.23 | +0.15 | +39.47% |
| May 31, 2024 | Mar 1, 2024 | -0.42 | -0.29 | +0.13 | +30.95% |
| Feb 8, 2024 | Dec 1, 2023 | -0.41 | -0.40 | +0.01 | +2.44% |
| Nov 9, 2023 | Sep 1, 2023 | -0.43 | -0.46 | -0.03 | -6.98% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2019 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 13, 2018 | HC Wainwright & Co. | init | — | Buy |
| Nov 10, 2017 | Raymond James | down | Outperform | Market Perform |
| Jan 25, 2017 | Raymond James | init | — | Outperform |
| Dec 15, 2016 | BTIG | init | — | Buy |
| Nov 28, 2016 | Evercore ISI Group | init | — | Buy |
About Organovo Holdings, Inc.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- organovo.com
News
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
- Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected
- Nasdaq Gains Over 1%; Williams-Sonoma Shares Plunge After Q4 Results
- Dow Surges 200 Points; Keurig Dr Pepper Posts Upbeat Earnings
- Nasdaq Dips 1.5%; Home Depot Issues Weak Forecast
- Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on ONVO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN DOUGLAS JAY | Director | Stock Award(Grant) | Aug 6, 2024 | 70,821 |
| GOBEL DAVID | Director | Stock Award(Grant) | Aug 6, 2024 | 39,214 |
| JOSHI VAIDEHI | Director | Stock Award(Grant) | Aug 6, 2024 | 58,821 |
| MILHOUS ALISON TJOSVOLD | Director | Stock Award(Grant) | Aug 6, 2024 | 58,821 |
| MURPHY KEITH E | Officer and Director | Stock Award(Grant) | Aug 6, 2024 | 132,641 |
| STERN ADAM K. | Director | Stock Award(Grant) | Aug 6, 2024 | 58,821 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.93% | 1,218,000 | 415.09K | Sep 29, 2024 |
| Prescott Group Capital Management, L.L.C. | 2.69% | 414,035 | 141.10K | Sep 29, 2024 |
| Vanguard Group Inc | 2.26% | 347,487 | 118.42K | Sep 29, 2024 |
| Blackrock Inc. | 0.93% | 142,208 | 48.46K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.82% | 125,479 | 42.76K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.29% | 44,028 | 15.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.53% | 234,506 | 79.92K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 114,640 | 39.07K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 83,248 | 28.37K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 19,617 | 6.68K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 11,895 | 4.05K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 4,727 | 1.61K | Oct 30, 2024 |